Galectin Therapeutics Inc.

Contributing Author

Recent Articles by Galectin Therapeutics Inc.

Nov-14	Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update GALT GlobeNewswire
Nov-10	Galectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual Meeting GALT GlobeNewswire
Oct-20	Galectin Therapeutics to Present at the H.C. Wainwright 9th Annual MASH Investor Conference GALT GlobeNewswire
Oct-07	Galectin Therapeutics to Present at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2025 GALT GlobeNewswire
Sep-02	Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference GALT GlobeNewswire
Aug-14	Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2025 and Provides Business Update GALT GlobeNewswire
Jul-09	Galectin Therapeutics Announces New $10 Million Credit Line from Richard E. Uihlein, Sufficient to Cover Expected Expenditures Through June 2026 GALT GlobeNewswire
Jun-10	Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension GALT GlobeNewswire
May-15	Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2025 and Provides Business Update GALT GlobeNewswire
May-12	Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress GALT GlobeNewswire